Evidence map›Paper›PMID 42443918›Full record

ArticleJournal of translational medicine2026

Australian registry reports poor health and wellbeing in people living with ME/CFS.

Natalie Eaton-Fitch, Sonya Marshall-Gradisnik

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Natalie Eaton-FitchNational Centre for Neuroimmunology and Emerging Diseases, Health Group, Griffith University, Gold Coast, Australia. n.eaton-fitch@griffith.edu.au.ORCID http://orcid.org/0000-0002-0815-3162
Sonya Marshall-GradisnikNational Centre for Neuroimmunology and Emerging Diseases, Health Group, Griffith University, Gold Coast, Australia.

Funding

National Health and Medical Research Council National Health and Medical Research CouncilStafford Fox Medical Research Foundation Stafford Fox Medical Research Foundation
6 · The paper itself

Abstract

introductionMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating condition hallmarked by post-exertional malaise accompanied by an array of multisystemic symptoms. Consequently, people living with ME/CFS experience significant health impacts and report poor health-related quality of life (HRQoL). Living with a condition of an area of unmet need, there is a call for a greater understanding of the health impacts of ME/CFS in Australia. Despite growing recognition and awareness, large-scale national comparative investigations using ME/CFS cohorts have not been reported.

methodsThe National Centre for Neuroimmunology and Emerging Diseases houses a significant Australian registry of people with ME/CFS. Self-reported questionnaire data collected from people with ME/CFS and non-fatigued controls (NFC) between 2014 and February 2026 was exported from applications including Research Electronic Data Capture (REDCap) and LimeSurvey. Data was collected pertaining to the sociodemographic background, medical history, symptom presentation (for people with ME/CFS), and validated patient reported outcome measures to assess HRQoL. The questionnaire covered medical history, routine medications, symptom presentation, and HRQoL, using validated tools including the 36-item short form health survey (SF-36). Data was analysed using independent student's t and chi-square tests, linear regression analysis, principal component analysis (PCA), and k-means clustering. Data was presented as mean and standard deviation or percentages. Statistical analysis was completed using SPSS and RStudio with a significance set at p < 0.05.

resultsResponses were analysed from n = 797 NFC (41.72 ± 13.86 years, 62.6% female) and n = 2,873 people with ME/CFS (44.85 ± 13.77 years, 75.2% female). Participants with ME/CFS fulfilled Fukuda (39.0%), CCC (30.4%) and ICC (30.6%) case definitions. Analysis of symptom presentation differed in both severity and frequency according to the most stringent case definition met; however, this did not predict poor HRQoL outcomes. HRQoL was significantly impaired compared with NFC, and people fulfilling ICC were more likely to report poorer outcomes. Regression analysis revealed the impact of multisystemic symptoms on both physical and mental functioning. K means clustering returned four clusters which differed according to stringent case criteria met, severity and frequency of symptoms.

conclusionThis large-scale national investigation highlights the significant symptom burden and reduced HRQoL in people with ME/CFS. These findings emphasise the need for tailored clinical approaches and further research into symptom clustering for the purpose of identifying clinical subtypes.

Indexed as

Fatigue Syndrome, ChronicHealthRegistriesAdultAustraliaFemaleHealth StatusHumansMaleMiddle AgedPsychological Well-BeingQuality of LifeSurveys and Questionnaires

Identifiers

PMID42443918
PMCPMC13647591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.